美国FDA批准实验室肺癌药物的股票上涨

你懂吗

美国FDA批准实验室肺癌药物的股票上涨

来自：MACD论坛(bbs.shudaoyoufang.com) 作者：你懂吗 浏览：16158 回复：0

Shares of Discovery Laboratories Inc (DSCO.O) jumped 44 percent to their year high on Wednesday, after U.S. health regulators approved its drug for prevention of a breathing illness in premature infants.
The Warrington, Pennsylvania-based company's shares were trading up 19 percent at $4.45 on Wednesday on the Nasdaq. The stock, which touched a high of $5.39 earlier in the session, was one of the top percentage gainers on the exchange.
On a conference call with analysts, the company said it will market the drug Surfaxin, which it plans to launch in late-2012, on its own in the United States. Discovery Laboratories is looking for partners to market it internationally.
On Tuesday, the U.S. Food and Drug Administration approved Surfaxin for preventing respiratory distress syndrome (RDS)-- a condition in which lungs of premature infants are not able to produce enough surfactant.
Surfactant is a liquid that coats the inside of the lungs and helps to keep them open. Without enough surfactant, the lungs collapse.
About 90,000 premature infants in the United States are treated annually with currently available animal-derived surfactants, according to the company.
Surfaxin will be the first synthetic surfactant approved for the prevention of RDS.
In addition to Surfaxin, the company's surfactant pipeline includes two more products -- Surfaxin LS and Aerosurf -- which are in mid-stage trials.
The company's surfactant franchise has the potential to achieve peak sales of over $1 billion worldwide in the infant RDS market, Roth Capital analyst David Moskowitz said in a note to clients. He raised the price target on the company's stock to $10 from $6.
In February, the company got approval for the device Afectair, to deliver medicine to patients on ventilator support. Afectair is also expected to be launched this year
The company expects to spend about $12 million to $13 million annually on the launch of Surfaxin and Afectair, it said on the call.
愉检测实验室公司（股份DSCO.O）跃升44％，其年高周三，美国医疗监管机构批准后，其在早产儿的呼吸疾病的预防药物。
灵顿，[url=www.4u4ad.com/ic/pingan.html]平安车险官网[/url宾夕法尼亚州的公司的股份交易4.45美元，19％，上周三在纳斯达克。股票，感动在本届会议早些时候5.39美元的高点，是一个对汇率的百分比涨幅居前。
与分析师的电话会议上，该公司表示，将产品推向市场的的药物Surfaxin，它计划在2012年年底推出自身在美国。发现实验室正在寻找国际合作伙伴推向市场。
周二，美国食品和药物管理局批准，以防止呼吸窘迫综合征（RDS）Surfaxin - 这种情况在早产儿的肺部无法产生足够的表面活性剂。
表面活性剂是一种液体，大衣里面的肺部和有助于保持他们打开。如果没有足够的表面活性剂，肺部塌陷。
每年约90,000早产儿在美国被视为与现有的动物源性表面活性剂，根据该公司。
surfaxin将是第一个合成表面活性剂，为预防RDS的批准。
在该公司的表面活性剂管道除了Surfaxin，包括两个产品 - Surfaxin LS和Aerosurf - 在中期阶段的试验。
该公司的表面活性剂的专营权，有潜力，以实现婴儿的RDS市场在全球超过10亿美元的销售高峰，罗斯资本分析师David Moskowitz表示，在给客户的报告。他提出的关于该公司的股票目标价格从6美元到10美元。
今年二月，该公司为设备Afectair批准，呼吸机支持患者提供药品。afectair也预计将于今年推出。
该公司预计花费上推出的Surfaxin和Afectair每年约12万至13万，在电话会议上说。